6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Decreased sphingomyelin (t34:1) is a candidate predictor for lung squamous cell carcinoma recurrence after radical surgery: a case-control study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          To reduce disease recurrence after radical surgery for lung squamous cell carcinomas (SQCCs), accurate prediction of recurrent high-risk patients is required for efficient patient selection for adjuvant chemotherapy. Because treatment modalities for recurrent lung SQCCs are scarce compared to lung adenocarcinomas (ADCs), accurately selecting lung SQCC patients for adjuvant chemotherapy after radical surgery is highly important. Predicting lung cancer recurrence with high objectivity is difficult with conventional histopathological prognostic factors; therefore, identification of a novel predictor is expected to be highly beneficial. Lipid metabolism alterations in cancers are known to contribute to cancer progression. Previously, we found that increased sphingomyelin (SM)(d35:1) in lung ADCs is a candidate for an objective recurrence predictor. However, no lipid predictors for lung SQCC recurrence have been identified to date. This study aims to identify candidate lipid predictors for lung SQCC recurrence after radical surgery.

          Methods

          Recurrent ( n = 5) and non-recurrent ( n = 6) cases of lung SQCC patients who underwent radical surgery were assigned to recurrent and non-recurrent groups, respectively. Extracted lipids from frozen tissue samples of primary lung SQCC were analyzed by liquid chromatography-tandem mass spectrometry. Candidate lipid predictors were screened by comparing the relative expression levels between the recurrent and non-recurrent groups. To compare lipidomic characteristics associated with recurrent SQCCs and ADCs, a meta-analysis combining SQCC ( n = 11) and ADC ( n = 20) cohorts was conducted.

          Results

          Among 1745 screened lipid species, five species were decreased (≤ 0.5 fold change; P < 0.05) and one was increased (≥ 2 fold change; P < 0.05) in the recurrent group. Among the six candidates, the top three final candidates (selected by AUC assessment) were all decreased SM(t34:1) species, showing strong performance in recurrence prediction that is equivalent to that of histopathological prognostic factors. Meta-analysis indicated that decreases in a limited number of SM species were observed in the SQCC cohort as a lipidomic characteristic associated with recurrence, in contrast, significant increases in a broad range of lipids (including SM species) were observed in the ADC cohort.

          Conclusion

          We identified decreased SM(t34:1) as a novel candidate predictor for lung SQCC recurrence. Lung SQCCs and ADCs have opposite lipidomic characteristics concerning for recurrence risk.

          Trial registration

          This retrospective study was registered at the UMIN Clinical Trial Registry ( UMIN000039202) on January 21, 2020.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12885-021-08948-5.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          The biology and management of non-small cell lung cancer.

          Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

              The IASLC Staging and Prognostic Factors Committee has collected a new database of 94,708 cases donated from 35 sources in 16 countries around the globe. This has now been analysed by our statistical partners at Cancer Research And Biostatistics and, in close collaboration with the members of the committee proposals have been developed for the T, N, and M categories of the 8th edition of the TNM Classification for lung cancer due to be published late 2016. In this publication we describe the methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition.
                Bookmark

                Author and article information

                Contributors
                kahyo@hama-med.ac.jp
                Journal
                BMC Cancer
                BMC Cancer
                BMC Cancer
                BioMed Central (London )
                1471-2407
                17 November 2021
                17 November 2021
                2021
                : 21
                : 1232
                Affiliations
                [1 ]GRID grid.505613.4, ISNI 0000 0000 8937 6696, Department of Cellular and Molecular Anatomy, , Hamamatsu University School of Medicine, ; 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka, 431-3192 Japan
                [2 ]GRID grid.505613.4, ISNI 0000 0000 8937 6696, First Department of Surgery, , Hamamatsu University School of Medicine, ; 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka, 431-3192 Japan
                [3 ]GRID grid.505613.4, ISNI 0000 0000 8937 6696, Department of Tumor Pathology, , Hamamatsu University School of Medicine, ; 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka, 431-3192 Japan
                [4 ]GRID grid.505613.4, ISNI 0000 0000 8937 6696, Advanced Research Facilities & Services, , Hamamatsu University School of Medicine, ; 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka, 431-3192 Japan
                [5 ]Preppers Co. Ltd., 1-23-17 Kitashinagawa, Shinagawa Ward, Tokyo, 140-0001 Japan
                [6 ]GRID grid.505613.4, ISNI 0000 0000 8937 6696, International Mass Imaging Center, , Hamamatsu University School of Medicine, ; 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka, 431-3192 Japan
                [7 ]GRID grid.505613.4, ISNI 0000 0000 8937 6696, Department of Systems Molecular Anatomy, , Institute for Medical Photonics Research, Hamamatsu University School of Medicine, ; 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka, 431-3192 Japan
                Article
                8948
                10.1186/s12885-021-08948-5
                8597230
                34789180
                1b65ea7c-6086-477e-808a-5e4aa8e2e5ef
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 28 September 2020
                : 1 November 2021
                Funding
                Funded by: Hamamatsu University School of Medicine
                Award ID: HUSM Grant-in-Aid
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001700, Ministry of Education, Culture, Sports, Science and Technology;
                Award ID: JPMXS0450200221
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100009619, Japan Agency for Medical Research and Development;
                Award ID: JP20gm0910004
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2021

                Oncology & Radiotherapy
                lung squamous cell carcinoma,prognostic factor,recurrence prediction,lipid,mass spectrometry

                Comments

                Comment on this article